Researchers at Washington University School of Medicine in St. Louis have enrolled the first participants in an international clinical trial designed to prevent Alzheimer’s.

Alzheimer’s disease is a progressive neurological disorder that primarily affects older adults, leading to memory loss, cognitive decline, and behavioral changes. It is the most common cause of dementia. The disease is characterized by the buildup of amyloid plaques and tau tangles in the brain, which disrupt cell function and communication. There is currently no cure, and treatments focus on managing symptoms and improving quality of life.

A new study suggests that creativity maps onto a common brain circuit and that injury and neurological disease have the potential to unleash creativity. Researchers analyzed 857 participants across 36 fMRI brain imaging studies to identify a common brain circuit for creativity.

Summary: New research provides direct evidence that the gut microbiome communicates with the brain through the vagus nerve. Using germ-free mice, scientists observed significantly reduced vagal nerve activity, which returned to normal after introducing gut bacteria.

When antibiotics were used to eliminate bacteria in normal mice, vagal activity dropped but was restored when microbiome-derived intestinal fluids were reintroduced. Specific metabolites, including short-chain fatty acids and bile acids, were identified as key activators of vagal neurons.

These signals extended to the brainstem, confirming a clear gut-to-brain pathway. The findings advance understanding of the gut-brain axis and may lead to new treatments for neurological and gastrointestinal disorders.